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1 Background  
    Mature T-/NK-cell neoplasms are a heterogeneous group of non-Hodgkin lymphoma, 
which accounts for only 6% of all lymphoid neoplasms.1 Among them, angioimmunoblastic 
T-cell lymphoma (AITL)  and peripheral T-cell lymphoma, not otherwise specified (PTCL-
NOS) are two major subtypes. Both of them are nodal T-cell lymphomas. AITL accounts for 
18.5% of mature T-/NK-cell neoplasms.2 AITL is characterized by specific clinical features, 
including generalized lymphadenopathy, high fever, skin rash, and autoimmune-like 
manifestations. AITL tumor cells share characteristics with follicular helper T cells (Tfh), 
expressing B-cell lymphoma protein 6 (BCL6), a transcription factor; C-X-C motif receptor 5 
(CXCR5), a chemokine receptor; C-X-C motif ligand 13 (CXCL13), a chemokine; and 
programmed death-1 (PD1), a member of the CD28 costimulatory membrane receptor family. 
AITL tissues display prominent infiltration of inflammatory cells, follicular dendritic cell 
meshwork formation, and branching vascular structures (Figure 1).  
 
Figure 1: Pathology of Angioimmunoblastic T-cell lymphoma (AITL), image from Philippe Gaulard et 
al.3 (A) Pattern III AITL comprising a diffuse polymorphous infiltrate associated with abundant microvessels 
(*);  the neoplastic component comprises small to medium-sized lymphoid cells with clear cytoplasm, which are 
admixed with a reactive component comprising eosinophils, plasma cells, mononucleate histiocytes and large 
immunoblastic cells (arrows) (HE, X400); (B) dense follicular dendritic cell meshwork surrounding the vessels 
(*) and enveloping the cellular infiltrate demonstrated by a CD21 immunostain (immunoperoxidase, X200); (C) 
scattered B-cell immunoblasts demonstated by a CD20 immunostain (immunoperoxidase, X400); (D) neoplastic 
Tfh cells highlighted by an ICOS immunostain rosseting of the around a B-cell blast (immunoperoxidase, X400). 
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PTCL-NOS account for 25.9% of mature T-/NK-cell neoplasms 2 and some of them exhibit 
several features reminiscent of AITL, although they do not show the typical morphology of 
AITL. Prevalent gene mutations including those in  ras homolog family member A (RHOA), 
isocitrate dehydrogenase 2 (IDH2), ten-eleven translocation 2 (TET2), and DNA 
methyltransferase 3A (DNMT3A) have been identified in these subtypes recently.4-6 
   RHOA encodes a small GTPase serving as an intracellular molecular switch which  cycles 
between a GTP-bound active form and a GDP-bound inactive form through GEF. The active 
form of  RHOA transduces signals and regulates multiple cellular progresses though direct 
interaction with downstream effectors.7 G17V RHOA mutation was identified in 53-71% of 
AITLs and 63% of AITL-like PTCL-NOS.4-6  G17V RHOA mutant binds tightly with GEF 
and decrease the active RHOA.5 However, the role of this mutant in AITL and PTCL-NOS 
has not been understood. 
   IDH2 catalyzes the interconversion of isocitrate into alpha-ketoglutarate (α-KG), an 
essential cofactor for many enzymes, including JmjC domain-containing histone 
demethylases, TET 5-methylcytosine hydroxylases and EgIN prolyl-4-hydroxylases. Cancer-
associated IDH2 mutations alter the enzymes such that they reduce α-KG to the structurally 
similar metabolite R-2-hydroxyglutarate (R-2HG) inhibiting the function of wide type 
TET2.8 IDH2 mutations, including R127 K/G/T/S IDH2 and R140G IDH2 mutation were 
defined in 20-45% of AITLs.9 
   TET2  encodes TET enzymes which are 2-oxyglutarate, oxygen- and iron-dependent 
dioxygenases able to catalyze the oxidation of 5-methylcytosine (5-mC) into 5-
hydroxylmethylcytosine (5-hmC). They have been identified as key players in cytosine 
demethylation and in the control of cellular differentiation and transformation. Loss of TET2 
function will lead to hypermethylation of promoters of  differentiation genes and negative 
regulators of self-renewal genes, inhibiting the activations of those genes.  TET2 mutations 
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were identified in 33-83% of AITLs and in 20-49% PTCL-NOS.10  
   DNMT3A enhances the methylation progress, adding a methyl group to the C5 position of 
the pyrimidine ring of cytosine to form 5mC. Loss of DNMT3A function will lead to 
hypomethylation of promoters of self-renewal genes and negative regulators of differentiation 
genes, inhibiting the activations of those genes. In mature T-/NK-cell neoplasms, DNMT3A 
mutations are clustered in the methylase domain.11 DNMT3A mutations were identified in 
26.1% of AITLs and in 27.3% of  PTCL-NOS.5 
   Cancer develops from an individual cell that accumulates acquired mutations. Chronic 
lymphotic leukemia, a common leukemia originated from B lymphocytes, develops from the 
pre-leukemic multipotent hematopoietic progenitors carrying somatic mutations.12 Similarly,  
the TET2 and DNMT3A mutations found in AITL and PTCL-NOS were proposed to arise in 
hematopoietic stem/progenitors upstream to the T-lymphocyte lineage commitment in a few 
cases.13  Previously, our lab also reported that the TET2 and DNMT3A mutations were 
identified in non-tumor tissues together with tumor tissue in these subtypes.5 However, the 
molecular pathogenesis of AITL and PTCL-NOS has not been well understood. 
2 Purpose: 
   We conducted this research to find out cellular origin of the frequent gene mutations 
(TET2/DNMT3A/IDH2/RHOA) in AITL and PTCL-NOS. 
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Figure 2: Research question of the research 
The figure shows the hematopoietic stem cell differentiation hierarchy. Tumor cells of AITL and PTCL-NOS are 
T follicular helper. The arrows point out the cells in which frequent gene mutations 
(TET2/DNMT3A/RHOA/IDH2) may occur. 
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3 Materials and Methods: 
 
 
Figure 3: Outlines of patients and methods 
3.1 Patients and samples 
   Lymph node biopsy samples were obtained from 27 patients  with AITL (n=19) and PTCL-
NOS (n=8) and used after approval by the local ethics committees in all the participating 
institutes (Supplementary Table 1). Informed consent was obtained from all living subjects.  
Among 27 patients, 10 patients (PTCL13, PTCL14, PTCL159, PTCL160, TO3, MITO4, 
MITO12, TS4, TS5, and TS8) were further collected peripheral blood, bone marrow and 
mucosa buccal. PTCL14 patient’s nails were collected.  
3.2 Mutation profiles of patients evolved in the research 
   The mutation profiles targeting DNMT3A/IDH2/RHOA/TET2 of  27 AITL and PTCL-NOS 
patients were identified by deep sequencing using Ion PGM (Life Technologies). This 
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analysis was performed previously. The results  were shown in Figure 4 and Supplementary 
Table 2.  
 
Figure 4: Mutation profiles of AITL and PTCL-NOS patients. The green, orange, red, and blue boxes 
indicate positive DNMT3A, IDH2, RHOA, and TET2 mutations, respectively. The white box indicates negative 
DNMT3A, IDH2, RHOA, and TET2 mutations. 
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3.3 Sorting of tumor cell-enriched fraction and other fractions   
   Mononuclear cells (MNCs) were isolated from peripheral blood (PB) of the patient using 
Ficoll-PaqueTM PLUS (GE healthcare) following the manufacture’s protocol. MNCs were 
stained by fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (BD Biosciences, 555346), 
anti-CD14 antibody (BD Biosciences, 555397), and phycoerythrin (PE)-conjugated anti-CD8 
(Dako, clone DK25), anti-CD19 antibody (Dako, clone HD37), and allphycocyanin (APC)-
conjugated anti-CD279/PD1 antibody (Bio Legend, clone EH12.2H7), and then fractionated 
by FACS Aria (BD Biosciences).  
3.4 Immunohistochemistry 
   Paraformaldehyde-lysine-periodate (PLP) tissues were cut in a cryostat at -22oC into 5um 
sections and mounted on PEN-Membrane slides (Leica). Tissue sections were stained with 
mouse anti-human PD1 (NAT105 ab52587, Abcam) and anti-human CD20cy (clone L26, 
Dako) antibodies and detected by Envison TM+ Dual Link system-HRP (Dako). Then, tissue 
sections were counterstained with Hematoxylin (Mayer Hematoxylin, Muto Pure Chemical 
Co LTD) in 20 seconds at room temperature. After staining, tissue sections were dehydrated 
with ethanol and dried at room temperature before laser microdissection. 
3.5 Laser microdissection 
   Laser microdissection was performed using LMD700 (Leica). Cells which were positive 
with either PD1 or CD20 were dissected and  collected into caps of 0.2 ml PCR tubes 
(Takara) containing 20ul of distill water. Approximate 100,000um2 of dissected cells were 
collected for each sample.  
3.6 DNA extraction 
   High molecular weight genomic DNA was extracted from lymph node specimens which 
were frozen fresh or after fixation. Genomic DNA of the sorted cells was directly amplified 
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using Repli G single cell kit (Qiagen). Genomic DNA  of the laser microdissected cells was 
extracted using  QIAamp DNA PFFE Tissue kit (Qiagen).  
3.7 PCR 
   The amplified DNA solution from sorted cells was diluted 100 times and 2ul of this was 
used for PCR  under  the following conditions:  94oC for 2 minutes, 35 cycles of 98oC for  10 
seconds and 68oC for 30 seconds by KOD -Plus- Neo kit (Toyobo) with each primer set 
(Supplemental table 3).  
   The DNA from dissected cells was not diluted and 1ul of this  was used for PCR under the 
following conditions:  95oC for 15 minutes, 60oC for 4 minutes, 72oC for 4 minutes,  35 to 40 
cycles of 95oC for 1 minute, 60oC for 1 minute, 72oC for 1 minute, and 72oC for 10 minutes 
by AmpliTaq Gold  360 kit (Applied Biosystems) with each primer set (Supplemental table 
3).  
3.8 Sanger sequencing 
   PCR products were purified by either gel extraction kit (Qiagen) or Exosap IT enzyme 
according to the manufacture’s protocols. Then, 1 or 2ul of purified PCR product were used 
for Sanger sequencing using BigDye 3.1 kit (Qiagen). The results were analyzed using DNA 
Sequencer 3130 (Life technologies) and the Chromalite software. 
3.9 PCR-based deep sequencing by Ion PGM 
   The allele frequencies of the mutations in the whole tumor, in the sorted cells and in the 
dissected cells were identified using PCR-based deep sequencing by Ion PGM (Life 
Technologies). The samples were subjected to genomic PCR to amplify the regions 
containing gene mutations using the primers listed in Supplemental Table 3. Libraries were 
prepared by the Ion Plus Fragment Library kit (Life Technologies) according to the 
manufacturer’s instruction and then sequenced by Ion PGM (Life Technologies) using 318 
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Chip (Life Technologies). The data was analyzed by Variant Caller 3.6 (Life Technologies). 
The single nucleotide variant comprising equal to or more than 0.5% were adopted as the 
mutation. 
3.10 Colony forming analysis from peripheral blood mononuclear cells (PB MNCs) 
   Total PB MNCs were isolated and cultured in MethoCult H4435 Enriched (Stemcell 
Technologies) for 15 days. Each colony was harvested. Genomic DNA of the colonies was 
directly amplified using Repli G single cell kit (Qiagen). The DNA solution was diluted 100 
times and 2ul of these were used for Sanger sequencing.  
4 Results 
4.1 Flowcytometry results: 
4.1.1 Double somatic mosaic mutations in TET2 and DNMT3A – origin of peripheral T-cell 
lymphoma: a case report (published in Annals of Hematology, 2015) 
   A 74 year-old male patient (PTCL14) was admitted to the hospital due to generalized 
lymphadenopathy. He was diagnosed as having PTCL-NOS by excision biopsy of the 
swollen lymph node. 
   Targeted sequencing was performed to clarify the mutational profiles for the genomic DNA 
extracted from the lymph node. Mutations in TET2 c.A3443G:p.Y1148C and DNMT3A 
c.T2264C:p.F755S were found at the allele frequencies of 24.8% and 23.9%, respectively. 
Despite the absence of lymphoma cell infiltration in bone marrow on a pathologic study, both 
mutations were identified in genomic DNA collected from bone marrow cells at the similar 
allele frequencies in each gene. This data suggested that the mutations pre-existed in 
hematopoietic cells before the tumor development.  
   To further elucidate the mutational cell origin, we sorted the peripheral blood mononuclear 
cells (PB MNCs) into CD4+PD1+, CD4+PD1-, and CD8+ T lymphocyte; CD19+ B 
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lymphocyte; and CD14+ monocyte fractions (Figure 5). CD4+PD1+ lymphocytes, supposed 
to be enriched for tumor cells, showed identical mutations in TET2 and DNMT3A at the allele 
frequencies of 46.1% and 50.0%, respectively, indicating that whole this population 
comprises a single clone having both mutations at a heterozygous state (Figure 6). The 
identical TET2 and DNMT3A mutations were also detected in CD19+ B lymphocytes; 
CD4+PD1- and CD8+ T lymphocytes; and CD14+ monocytes, at the allele frequencies (13.8-
24.9% and 17.7-22.2%, respectively) comparable to those in the lymph node (24.8% and 
23.9%, respectively) (Figure 6). 
 
Figure 5: The purity of sorted cells from PB MNCs of PTCL14. 
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   We further assessed genomic lesions in hematopoietic progenitors in PB at a single-cell 
level by sequencing genomic DNA prepared from PB cell-derived colonies. PB MNCs were 
cultured in MethoCult H4435 Enriched for 15 days. Genomic DNA from each colony was 
directly amplified using Repli G single cell kit. Identical DNMT3A and TET2 mutations were 
found in 38 out of 120 (31.7%) colonies at a heterozygous state (Figure 6c). All the 38 
colonies had both mutations by Sanger sequencing, with no exceptions having only one of the 
two. These data suggest that the mutations were acquired at least in or earlier than multi-
potent hematopoietic progenitor stage. Unfortunately, the living bone marrow cells suitable 
for cell purification were not available. 
   A further analysis of these mutations in buccal mucosa and nail were performed to seek the 
origin of these mutations. TET2 and DNMT3A mutations were detected in the buccal mucosa 
with the allele frequencies of 11.9% (range, 10.6%-13.3%) and 8.1% (2.0%-14.2%), and in 
the nail with the allele frequencies of 0.9% (0.7%-1.1%) and 0.8% (0.5%-1.2%) in three 
independent deep sequencing runs (Figure 6b). Given that the low allele frequencies of these 
mutations in the nail DNA may be the errors of the platform, we performed deep sequencing 
for 9 healthy nail DNA samples as negative controls. The coverages of sequence reads and 
the actual frequencies of mutation reads were described in Table 1 (621 G reads for TET2 and 
262 G reads for DNMT3A). The mutation allele frequencies in the nail of the patient were 
approximately 90-times (for TET2) and 40-times (for DNMT3A) higher than the frequencies 
of random single nucleotide variant read at the specific site in the negative control DNA, in 
three independent sequencing procedures (p<0.05 for DNMT3A and p<0.01 for TET2). This 
implies that those mutated allele frequencies are not technical errors. 
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Figure 6: Distribution of TET2 and DNMT3A mutations in each cell fraction and tissue of PTCL14 
a. Chromatogram of TET2 c.A3443G p.Y1148C and DNMT3A c.T2264C:p.F755S mutations. 
b. Allele frequencies determined by deep sequencing. The X axis shows the cell fractions and the Y axis 
shows the   allele frequencies. Buccal, buccal swab; BM, bone marrow mononuclear cells; LN, lymph 
node. 
c. Sequencing analyses for peripheral blood mononuclear cell-derived colonies. 
 
 
Table 1: Average allele frequencies and coverage of TET2 c.A3443G:p.Y1148C and 
DNMT3A c.T2264C:p.F755S in control and patient nail DNA 
 
 
Control (n=9) Nail (n=3) 
p 
 
Average  Average   Average  Average   
 
allele coverage allele coverage   
 
frequencies (%)   frequencies (%)     
TET2 
0.01 24206.11 0.9 64415.5 <0.01 
 c.A3443G:p.Y1148C 
DNMT3A  
0.02 37191.89 0.82 31519.33 <0.05 
c.T2264C:p.F755S 
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4.1.2 T lymphoid progenitor was the cellular origin of TET2 and DNMT3A mutations in a 
case of PTCL-NOS 
   Patient PTCL 159 was diagnosed as PTCL-NOS. The mutation profile showed 
G17VRHOA, TET2 and DNMT3A mutations.  G17V RHOA mutation was identified only in 
CD4+ T cells with allele frequency of 7.1%. However, TET2 and DMMT3A mutations were 
identified in both CD4+ and CD8+ T cells (Figure 7). 
 
Figure 7: Distribution of TET2, DNMT3A and RHOA mutations in tumor and each cell fraction of 
PTCL159. Upper panel is the purity of sorted cells from peripheral blood. Lower panel is the allele frequencies 
of  RHOA, TET2  and DNMT3A mutations. 
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4.1.3 CD4+ T cell was the cellular origin of TET2, DNMT3A and G17V RHOA mutations 
in a case of AITL (published in Nature genetics, 2014) 
   PTCL160 was diagnosed AITL with pleural effusion.  The mutation profile showed G17V 
RHOA and TET2 mutations. RHOA and TET2 mutations were identified in lymph node, PB 
MNCs and CD4+ T cells. No mutations were found in CD8+, CD14+ and CD19+ cells 
(Figure 8).  
 
Figure 8: Distribution of TET2 and RHOA mutations in each cell fraction and tissue of PTCL160. Upper 
panel is the purity of sorted cells from pleural effusion fluid. Lower panel is the chromatogram of RHOA and 
TET2 mutations. 
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4.2 Laser microdissection results: 
4.2.1 G17V RHOA was tumor specific mutation in AITL and PTCL-NOS 
   In the flowcytometry cohort, we found that G17V RHOA were identified only in CD4+ T-
cells in 1 AITL and 1 PTCL-NOS. To gain further insight into the origin of the G17V RHOA 
mutation, we examined the mutation in laser-microdissected PD1+ and CD20+ B cells, 
assumed to be enriched and depleted in tumor cells, respectively, in 10 samples (9 AITLs and 
1 PTCL-NOS). The G17V RHOA mutation was detected only in the PD1+ cells but not in the 
CD20+ cells in all 10 samples (Figure 9). The allele frequencies of the G17V RHOA 
mutations in the dissected PD1+ cells were higher than those in the matched whole tumor 
samples. This finding strongly supports our hypothesis that the acquisition of the G17V 
RHOA mutation is a specific event in tumor cells. 
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Figure 9: RHOA mutations are specific to tumor cell-enriched fractions. Sanger sequences of G17V RHOA  
mutations in whole tumor, PD1+ cells, and CD20+ cells The gray background indicates angioimmunoblastic T-
cell lymphoma (AITL)  samples and the white background indicates peripheral T-cell lymphoma, not otherwise 
specified (PTCL-NOS) samples. The numbers indicate allele frequencies of mutations defined by amplicon-
based deep sequencing.*, RHOA c.A51T:p.G17V, synonymous mutation. 
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4.2.2 R172 IDH2 was tumor specific mutation in AITL 
   We  also checked the distribution of R172 IDH2 mutation in PD1+ and CD20+ cells in 4  
R172 IDH2-mutated samples. R172 IDH2 mutations were identified in PD1+ cells, but not in 
CD20+ cells in all 4 samples (PTCL8, PTCL61, PTCL63, and PTCL70) (Figure 10).  
 
 
Figure 10: IDH2 mutations are specific to tumor cell-enriched fractions. Sanger sequence of IDH2  mutations in whole 
tumor, PD1+ cells, and CD20+ cells.  The gray background indicates angioimmunoblastic T-cell lymphoma (AITL) samples. 
The numbers indicate allele frequencies of mutations defined by amplicon-based deep sequencing. 
 
4.2.3 Distributions of TET2 and DNMT3A mutations 
   In our laser microdissection cohort, 16 patients have TET2 mutations and 7 have DNMT3A 
mutations (Figure 4, Supplementary table 2). More than half of the TET2 mutants were 
located on Cystein-rich (Cys-rich) domain and core double-strain-beta-helix (DSBH) domain 
of TET2 and most of DNMT3A mutants located on S-adenosyl-L-methionine-dependent-
methyltransferase (SALMDM) domain of DNMT3A (Figure 11). Given that those domains 
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of TET2 and DNMT3A are catalytic domains, the TET2 and DNMT3A mutants in our cohort 
may have some functions in tumorigenesis of AITL and PTCL-NOS.  
 
Figure 11: Locations of TET2 and DNMT3A mutants on TET2 and DNMT3A. 
Cys-rich: Cystein-rich domain; Core-DSBH: Core double-strain-beta-helix domain; PWWP: PWWP domain; 
ADD: ADD domain; SALMDM: S-adenosyl-L-methionine-dependent-methyltransferase domain 
 
   We examined the distribution of TET2 and DNMT3A mutations in PD1+ and CD20+ cells. 
Twenty of 26 TET2 mutations were identified in both the PD1+ and the CD20+ cells (Table 
2), and 15 of 16 TET2-mutated samples had at least 1 mutation in both the PD1+ and the 
CD20+ cells (Figure 12). Concomitantly, DNMT3A mutations were identified in both the 
PD1+ and the CD20+ cells in 4 of 7 DNMT3A-mutated samples (Table 3, Figure 12).
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Table 2: TET2 mutations in dissected samples were defined by Sanger sequencing and amplicon-based sequencing 
Sample 
Mutation 
type 
REFSEQ 
Nucleotide 
change 
Amino acid 
Transcript 
Whole tumor PD1+ cells CD20+ cells 
Sanger (%) Sanger (%) Sanger (%) 
PTCL2 Nonsense NM_001127208 c.G2263T p.E755X positive 1.5 positive 86.6 positive 4.9 
PTCL2 Frameshift NM_001127208 c.5348delA p.Q1783fs positive 29.5 positive 16.6 positive 24.9 
PTCL8 Frameshift NM_001127208 c.3501_3501del p.1167_1167 del positive 6.8 positive 51.4 positive 28.7 
PTCL8 Frameshift NM_001127208 c.1355delA p.E452fs positive 5.8 positive 20.2 negative 0 
PTCL60 Frameshift NM_001127208 c.2475delA p.S825fs positive 10 positive 36.4 positive 47.5 
PTCL60 Missense NM_001127208 c.A4160G p.N1387S positive 12.6 positive 30.9 negative 0 
PTCL61 Frameshift NM_001127208 c.4192_4193insT p.L1398fs positive 42.1 positive 27.8 positive 36.1 
PTCL63 Nonsense NM_001127208 c.C2746T p.Q916X positive 17.1 positive 29.1 positive 11.7 
PTCL63 Missense NM_001127208 c.G4133T p.C1378F positive 21 positive 60.1 positive 45.1 
PTCL70 Frameshift NM_001127208 c.5477delA p.E1826fs positive 30.6 positive 31.6 positive 4.4 
PTCL77 Frameshift NM_001127208 c.5269delC p.H1757fs positive 13.8 positive 41.6 positive 24.8 
PTCL77 Missense NM_001127208 c.G5687C p.R1896T positive 16.8 positive 59.9 negative 0 
PTCL78 Nonsense NM_001127208 c.C2578T  p.Q860X positive 54.5 positive 79.7 negative 0 
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PTCL80 Nonsense NM_001127208 c.C1630T  p.R544X positive 32.5 positive 73.3 positive 100 
PTCL121 Nonsense  NM_001127208 c.C2626T p.Q876X positive 27.7 positive 44.1 positive 37.7 
PTCL121  Missense NM_001127208 c.G3866T p.C1289F positive 36.2 positive 50 negative 0 
PTCL123 Frameshift  NM_001127208 c.4657_4660del p.1553_1554del positive NA positive ND positive NA 
PTCL123 Missense  NM_001127208 c.A5642C p.H1881P positive 9.1 positive 25.8 negative 0 
PTCL127 Nonsense NM_001127208 c.C4889A p.S1630X positive NA positive ND positive NA 
PTCL127 Nonsense NM_001127208 c.C346T p.Q116X positive NA positive ND positive NA 
PTCL129 Frameshift  NM_001127208 c.2188_2189del p.730_730del positive 24.4 positive 59.5 positive 15.7 
PTCL129 Missense NM_001127208 c.T3965C p.L1322P positive NA positive ND positive NA 
PTCL136 Frameshift NM_001127208 c.1939_1940del p.647_647del positive 28 positive 23.9 positive 44.9 
PTCL136 Nonsense NM_001127208 c.C2305T p.Q769X positive 37.8 positive 34.9 positive 21.8 
PTCL142 Frameshift  NM_001127208 c.3534_3540del p.1178_1180del positive 20.2 positive 27.3 positive 54.5 
PTCL144 Missense  NM_001127208 c.C4104G p.F1368L positive 34.7 positive 26.3 positive 51 
NA:  not analyzed. The gray background indicates the case that TET2 mutation was identified in the whole tumor and the PD1+ cells not  
in the CD20+ cells. 
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Table 3: DNMT3A mutations in dissected samples were defined by Sanger sequencing and amplicon-based sequencing 
 
Sample 
Mutation 
type 
REFSEQ 
Nucleotide 
change 
Amino acid 
Transcript 
Whole tumor PD1+ CD20+ 
Sanger (%) Sanger (%) Sanger (%) 
PTCL2 Splice site NM_175629 c.2409-1G>A p.V690splice positive 30.6 positive 22.2 positive 41.5 
PTCL8 Missense NM_175629 c.G2207A p.R736H positive 5.6 positive 27.9 negative 0 
PTCL60 Missense NM_175629 c.T2251G p.F751V positive 11.5 positive 48.6 positive 6.2 
PTCL70 Missense NM_175629 c.G2207A p.R736H positive 35.7 positive 14.7 negative 0 
PTCL74 Splice site NM_175629 c.2478+1G>- p.L713splice positive 2.4 positive 27.9 negative 0 
PTCL127 Missense NM_153759 c.G2078A p.R693H positive 32 positive 55.7 positive 25.4 
PTCL136 Missense NM_153759 c.G1175C p.W392S positive 41.3 positive 56.9 positive 15.7 
The gray background indicates the cases that DNMT3A mutations were identified in the whole tumor and the PD1+ cells not  
in the CD20+ cell
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4.2.4 Summary of laser microdissection results 
   The results of laser microdissection cohort were summarized in Figure 12. We found that in 
AITL (PTCL2, PTCL8, PTCL61, PTCL77, PCTL136, PTCL142) and PTCL-NOS 
(PTCL127) patients, TET2 mutations were identified in both tumor and non-tumor cells while 
RHOA mutations were only identified in tumor cells. Likewise, IDH2 mutations were only 
identified in AITL patients (PTCL8, PTCL61, PTCL63, PTCL70) and co-occur with TET2 
and RHOA mutations. 
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Figure 12: Distributions of TET2/DNMT3A/RHOA/IDH2 mutations. Distributions of 
TET2/DNMT3A/RHOA/IDH2 mutations in whole tumor, PD1+ cells, and CD20+ cells of laser microdissected 
samples. The blue box represents positive TET2 mutation; the green box, positive DNMT3A mutation; the red 
box, positive RHOA mutation; the orange box, positive IDH2 mutation; and the white box, negative 
TET2/DNMT3A/RHOA/IDH2 mutations. The gray background indicates angioimmunoblastic T-cell lymphoma 
(AITL)  samples and the white background indicates peripheral T-cell lymphoma, not otherwise specified 
(PTCL-NOS) samples. The numbers indicate allele frequencies of mutations defined by amplicon-based deep 
sequencing. Multiple TET2 mutations were identified in the following samples: PTLC2, 8, 60, 63, 77, 136, 121, 
123, 127, and 129. 
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5 Discussions 
   By determining the distribution of frequent mutations (TET2/DNMT3A/RHOA/IDH2), we 
elucidated cellular origin of these mutations in AITL and PTCL-NOS. RHOA and IDH2 
mutations were identified in tumor cell-enriched fraction only, while TET2 and DNMT3A 
mutations were identified in both the tumor cell-enriched fraction and the non-tumor cell-
enriched (CD20-positive B cell-, CD14-positive monocyte-, CD8-positive T cell-, and CD4-
positive T cell-) fractions. These data suggest that in AITL and PTCL-NOS development, 
multistep tumorigenesis may progress in association with the differentiation of blood 
cells/lymphocytes.  
   Recent genetic studies have revealed that in several hematologic cancers, several gene 
mutations existed in preleukemic hematopoietic cells as well as in tumor cells14; examples are  
TET2 and/or DNMT3A mutations in acute myeloid leukemia15-17 and NOTCH1 and SF3B1 
mutations in chronic lymphocytic leukemia (CLL).12,18 Moreover, somatic mutations have 
been demonstrated in elderly individuals without hematologic malignancies: DNMT3A, 
ASXL1, and TET2 mutations frequently observed in hematologic malignancies were the most 
frequent in these cohorts.19-22  In AITL tissues, premalignant cells having TET2 and/or 
DNMT3A mutations may  differentiate not only into T-lineage tumor cells but also into B 
cells. The G17V RHOA mutations specifically existed in the tumor cells of PTCLs in all 12 
samples. These data imply that the G17V RHOA mutation occurred in TET2-mutated 
premalignant cells and, further, that it may facilitate the selective differentiation of TET2-
mutated premalignant cells into tumor cells with the Tfh phenotype. This possibility needs to 
be proven in the future.  
   Genetic mosaicism is known as the presence of two or more genetically distinct cell 
populations in a given organism. 23 Various somatic mosaic mutations (SMMs) have been 
known to play roles in cancer development. 24,25 In childhood hematologic malignancies, 
SMMs of oncogenic NRAS mutations have been reported in juvenile myelomonocytic 
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leukemia, while no SMMs were reported in adult hematologic malignancies. 26 Only one 
mutation is detected in most of SMMs. 24,25 Strikingly, there is one report describing that 
SMMs of KRAS and TET2 in a case with de novo childhood 
myelodysplastic/myeloproliferative disease.27 In our PCTL14 case, both TET2 and DNMT3A 
mutations might occur during embryogenesis before the emergence of HSCs, because these 
mutations were identified in buccal and nail, albeit at low frequencies. Similar allele 
frequencies between the two mutations in buccal and nail DNA also indicate that cells having 
both mutations dominated over cells having either one during mosaic formation. To the best 
of our knowledge, our case is the first report of double SMMs in adult. Thus, the origin of 
PTCLs could be traced back to mosaic cells during early embryogenesis in some cases. 
   Contamination is the major concern in most of cell isolation methods such as 
flowcytometry sorting and laser microdissection. In PTCL14, the low allele frequencies of 
TET2 and DNMT3A mutations in nail DNA samples may be caused the contamination of 
blood cells in the nails. However, because the approximate mutation allele frequencies in 
blood cell DNA were 10-30%, our data would be realized, without mosaicism, only if 
assuming that we had blood cell contamination at an approximate ratio of  2.7-9%. 
Macroscopically, this ratio was unlikely. Similarly, assessment of sample purity in laser 
microdissection is also difficult. Differentially displayed variant allele frequencies of each 
gene should be a good indicator of success in microdissection. 
 
6 Conclusion 
   By isolation of the tumor cell-enriched and non-tumor cell-enriched populations from PB or 
tumor tissue, we showed that TET2/DNMT3A mutations were identified in both cell 
populations while RHOA and IDH2 mutations were identified only in tumor cell-enriched 
population.  Furthermore, we also found that TET2/DNMT3A mutations were identified with 
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similar allele frequencies in both hematopoietic and somatic tissues in one PTCL-NOS 
patient. Thus, the origin of AITL and PTCL-NOS could be traced back to HSC/HPC or even 
embryonic stem cells (Figure 13). In conclusion, our finding demonstrated that the multistep 
in tumorigenesis may be the concept of AITL and PTCL-NOS. Understanding the 
pathogenesis helps us to have better management of AITL and PTCL-NOS in future. 
 
Figure 13: Multiple tumorigenesis in AITL and PTCL-NOS. The cell of origin of AITL and PTCL-NOS 
could be traced back to hematopoietic stem/progenitor cells or even embryonic stem cells. 
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8 Supplemental information 
Supplementary Table 1: List of samples  
Number Sample Status of DNA Diagnosis 
PTCL2 Tumor REPLI-g* AITL 
PTCL8 Tumor REPLI-g AITL 
PTCL13 Tumor REPLI-g AITL 
PTCL14 Tumor REPLI-g PTCL-NOS 
PTCL60 Tumor original AITL 
PTCL61 Tumor original AITL 
PTCL63 Tumor original AITL 
PTCL70 Tumor original AITL 
PTCL74 Tumor original AITL 
PTCL77 Tumor original AITL 
PTCL78 Tumor original AITL 
PTCL80 Tumor original AITL 
PTCL121 Tumor original PTCL-NOS 
PTCL123 Tumor original PTCL-NOS 
PTCL127 Tumor original PTCL-NOS 
PTCL129 Tumor original PTCL-NOS 
PTCL136 Tumor original AITL 
PTCL142 Tumor original AITL 
PTCL144 Tumor original AITL 
PTCL159 Tumor original PTCL-NOS 
PTCL160 Tumor original AITL 
TO3 Tumor original AITL 
MITO4 Tumor original AITL 
MITO12 Tumor original AITL 
TS4 Tumor original PTCL-NOS 
TS5 Tumor original PTCL-NOS 
TS8 Tumor original AITL 
* REPLI-g: whole genomic DNA was amplified using REPLI-g kit (Qiagen) 
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Supplementary Table 2: Mutation profile of AITL and PTCL-NOS patients  
Sample 
ID 
Genes Annotated genes 
Mutation 
Type 
Nucleotide 
Change 
Amino acid 
Transcript 
VAF 
PTCL2 DNMT3A NM_175629 Splice site c.2409-1G>A p.V690splice 0.43 
PTCL2 RHOA NM_001664 Missense c.G50T p.G17V 0.076 
PTCL2 TET2 NM_001127208 Nonsense c.G2263T p.E755X 0.258 
PTCL2 TET2 NM_001127208 Frameshift c.5348delA p.Q1783fs 0.692 
PTCL8 DNMT3A NM_175629 Missense c.G2207A p.R736H 0.029 
PTCL8 IDH2 NM_002168 Missense c.G515C p.R172T 0.077 
PTCL8 RHOA NM_001664 Missense c.G50T p.G17V 0.074 
PTCL8 TET2 NM_001127208 Frameshift c.1355delA p.E452fs 0.075 
PTCL13 DNMT3A NM_153759 Missense c.T1814G p.F605C 0.047 
PTCL13 TET2 NM_001127208 Frameshift c.1643delA p.Q548fs 0.028 
PTCL13 TET2 NM_001127208 Missense c.A1463T p.N488I 0.037 
PTCL14 DNMT3A NM_175629 Missense c.T2264C p.F755S 0.27 
PTCL14 TET2 NM_001127208 Missense c.A3443G p.Y1148C 0.180 
PTCL60 DNMT3A NM_175629 Missense c.T2251G p.F751V 0.106 
PTCL60 TET2 NM_001127208 Frameshift c.2475delA p.S825fs 0.136 
PTCL60 TET2 NM_001127208 Missense c.A4160G p.N1387S 0.159 
PTCL61 IDH2 NM_002168 Missense c.G515T p.R172M 0.041 
PTCL61 RHOA NM_001664 Missense c.G50T p.G17V 0.029 
PTCL61 TET2 NM_001127208 Frameshift c.4192_4193insT p.L1398fs 0.329 
PTCL63 IDH2 NM_002168 Missense c.G515A p.R172K 0.223 
PTCL63 RHOA NM_001664 Missense c.G50T p.G17V 0.189 
PTCL63 TET2 NM_001127208 Nonsense c.C2746T p.Q916X 0.223 
PTCL63 TET2 NM_001127208 Missense c.G4133T p.C1378F 0.227 
PTCL70 DNMT3A NM_175629 Missense c.G2207A p.R736H 0.216 
PTCL70 IDH2 NM_002168 Missense c.G516C p.R172S 0.069 
PTCL70 RHOA NM_001664 Missense c.G50T p.G17V 0.056 
PTCL70 TET2 NM_001127208 Frameshift c.5477delA p.E1826fs 0.298 
PTCL74 DNMT3A NM_175629 Splice site c.2478+1G>- p.L713splice 0.057 
PTCL77 RHOA NM_001664 Missense c.G50T p.G17V 0.105 
PTCL77 TET2 NM_001127208 Frameshift c.5269delC p.H1757fs 0.085 
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PTCL77 TET2 NM_001127208 Missense c.G5687C p.R1896T 0.092 
PTCL78 RHOA NM_001664 Missense c.G50T p.G17V 0.453 
PTCL78 TET2 NM_001127208 Nonsense c.C2578T  p.Q860X 0.630 
PTCL80 TET2 NM_001127208 Nonsense c.C1630T  p.R544X 0.286 
PTCL121 TET2 NM_001127208 Nonsense c.C2626T p.Q876X 0.289 
PTCL121 TET2 NM_001127208 Missense c.G3866T p.C1289F 0.308 
PTCL123 TET2 NM_001127208 Frameshift c.4657_4660del p.1553_1554del 0.046 
PTCL123 TET2 NM_001127208 Missense c.A5642C p.H1881P 0.1 
PTCL127 DNMT3A NM_153759 Missense c.G2078A p.R693H 0.352 
PTCL127 RHOA NM_001664 Missense c.G50T p.G17V 0.248 
PTCL127 TET2 NM_001127208 Nonsense c.C4889A p.S1630X 0.434 
PTCL127 TET2 NM_001127208 Nonsense c.C346T p.Q116X 0.234 
PTCL129 TET2 NM_001127208 Frameshift c.2188_2189del p.730_730del 0.227 
PTCL129 TET2 NM_001127208 Missense c.T3965C p.L1322P 0.23 
PTCL136 DNMT3A NM_153759 Missense c.G1175C p.W392S 0.386 
PTCL136 RHOA NM_001664 Missense c.G50T p.G17V 0.089 
PTCL136 TET2 NM_001127208 Frameshift c.1939_1940del p.647_647del 0.213 
PTCL136 TET2 NM_001127208 Nonsense c.C2305T p.Q769X 0.058 
PTCL142 RHOA NM_001664 Missense c.G50T p.G17V 0.210 
PTCL142 TET2 NM_001127208 Frameshift c.3534_3540del p.1178_1180del 0.202 
PTCL144 TET2 NM_001127208 Missense c.C4104G p.F1368L 0.334 
PTCL144 TET2 NM_001127208 Nonsense c.C2305T p.Q769X 0.37 
PTCL159 DNMT3A NM_175629 Splice site exon22:c.2478+1G>A 0.118 
PTCL159 RHOA NM_001664 Missense c.G50T p.G17V 0.033 
PTCL159 TET2 NM_001127208 Nonsense c.C2200T p.Q734X 0.1 
PTCL159 TET2 NM_001127208 Missense c.C3391A p.P1131T 0.04 
PTCL159 TET2 NM_001127208 Missense c.G4133A p.C1378Y 0.051 
PTCL160 RHOA NM_001664 Missense c.G50T p.G17V 0.171 
PTCL160 TET2 NM_001127208 Frameshift c.2588_2609del p.863_870del 0.196 
PTCL160 TET2 NM_001127208 Missense c.C3391A p.P1131T 0.04 
TO3 IDH2 NM_002168 Missense c.G515T p.R172M 0.115 
TO3 RHOA NM_001664 Missense c.G50T p.G17V 0.114 
TO3 TET2 NM_001127208 Missense c.T5618C p.I1873T 0.118 
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MITO4 RHOA NM_001664 Missense c.G50T p.G17V 0.141 
MITO4 TET2 NM_001127208 Frameshift c.3812dupG p.C1271fs 0.293 
MITO4 TET2 NM_001127208 Missense c.G4391A p.C1464Y 0.025 
MITO12 RHOA NM_001664 Missense c.A377G p.H126R 0.04 
MITO12 RHOA NM_001664 Missense c.G50T p.G17V 0.162 
MITO12 TET2 NM_001127208 Nonsense c.C4546T p.R1516X 0.118 
MITO12 TET2 NM_001127208 Nonsense c.C4609T p.Q1537X 0.044 
TS4 DNMT3A NM_153759 Missense c.G315T p.E105D 0.076 
TS4 DNMT3A NM_022552 Missense c.C362T p.A121V 0.222 
TS4 TET2 NM_001127208 Missense c.G2567T p.G856V 0.031 
TS5 DNMT3A NM_022552 Missense c.G364A p.A122T 0.2 
TS5 DNMT3A NM_022552 Missense c.G361A p.A121T 0.2 
TS5 DNMT3A NM_022552 Missense c.G358A p.G120S 0.2 
TS5 TET2 NM_001127208 Missense c.G2567T p.G856V 0.036 
TS8 DNMT3A NM_022552 Missense c.C362T p.A121V 0.037 
TS8 RHOA NM_001664 Missense c.G50T p.G17V 0.061 
  
 
Supplementary Table 3: Primer list 
Gene Sample Primer Forward Reverse 
DNMT3A PTCL2 1 TCATCCTGCCCTTCCTTCT GTGCGTGATTTGGGGAAG 
DNMT3A PTCL8 1 TCAGGTGGGAAAGGCAGA TTGGCGAGTACCTGGCAT 
DNMT3A PTCL8 2 CCAGCTCCACAATGCAGA TGTCCTATGCAGACAGCCC 
DNMT3A PTCL14 1 AGTGAGCTGGCCAAACCAAG GGCCGGCTCTTCTTTGAGTT 
DNMT3A PTCL14 2 CAGGATGAAGCAGCAGTCCA CCCAGCTGATGGCTTTCTCT 
DNMT3A PTCL60 1 CCAGCTCCACAATGCAGA TGTCCTATGCAGACAGCCC 
DNMT3A PTCL70 1 CCAGCTCCACAATGCAGA TGTCCTATGCAGACAGCCC 
DNMT3A PTCL74 1 TCATCCTGCCCTTCCTTCT GTGCGTGATTTGGGGAAG 
IDH2 
  
CAAGAGGATGGCTAGGCGAG GCTGCAGTGGGACCACTATT 
RHOA 
  
GCCCCATGGTTACCAAAGCA ACATGGAAAATGGCATCAGTTGTT 
TET2 PTCL2 1 GGCAGCACAAACACAACCAT ATGAGTCTCGAACTCGCTTGA 
TET2 PTCL2 2 CCCAATCTGAGCAATCCAAACA AAGCCTCCTTGGACACAAGC 
TET2 PTCL8 1 CCTCCTCTTCCACAGGTTCC AGAAAGCATCGGAGAAGGGC 
TET2 PTCL8 2 TGCTTGGCGTAGACCTGTTT ACATCCCTGAGAACTTTTGCCT 
TET2 PTCL14 1 AGCCCTTAATGTGTAGTTGGGG GCTTTGTGTGTGAAGGCTGG 
TET2 PTCL14 2 TTGGGGGTTAAGCTTTGTGGA GCACAGTGTGTAGTGTTGGC 
TET2 PTCL60 1 CCAAATGGGACTGGAGGAAGT AGTTTTGGGTCTTGTTTCCTGC 
TET2 PTCL60 2 ACTACTTTCGCATTCACACACAC CTGCTAAGCTGTCCTCAGCC 
TET2 PTCL63 1 GGAGCAGAAGTCACAACAAGC GATGCCACCTTAGAGCAGCA 
TET2 PTCL63 2 ACTACTTTCGCATTCACACACAC CTGCTAAGCTGTCCTCAGCC 
TET2 PTCL70 1 GACATGCTTTCCCACACAGC TTGACCCATGAGTTGGAGCC 
TET2 PTCL77 1 GCAGGGAGATGGTTTCAGCA TGGAGATGCAGGGCATGAAG 
TET2 PTCL77 2 GGCTCCAACTCATGGGTCAA TCAGCCATTTTGGCTTCCCA 
TET2 PTCL78 1 TGGGACTGGAGGAAGTACAGA TCCTGTTCTTGAAAGCACCTGT 
TET2 PTCL80 1 ACCTCAAGCATAACCCACCA TGGGATTCCGCTTGGTGAAA 
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